自体T细胞疗法治疗HLA-A*02+患者的PRAME+晚期实体瘤:一项1期试验
这项首次人体、多中心、开放标签、3+3剂量递增/递减的1期试验研究IMA203——一种靶向PRAME的自体TCR T细胞疗法,用于HLA-A*02+的PRAME+复发和/或难治性实体瘤患者。1a期剂量递增入组27例,1b期剂量扩展入组13例;41例接受治疗者中严重细胞因子释放综合征发生率为4.9%(2/41),未出现严重神经毒性,未达到最大耐受剂量。40例接受IMA203治疗者中,未确认或确认缓解的总体缓解率为52.5%(21/40),确认缓解率为28.9%(11/38),中位缓解持续时间4.4个月(范围2.4-23.0,95%CI:2.6-未达到)。
要点
- IMA203 T细胞安全性可接受,未达到最大耐受剂量。
- 41例接受治疗者中严重细胞因子释放综合征发生率为4.9%(2/41),未发生严重神经毒性。
- 40例接受IMA203治疗者中未确认或确认缓解的总体缓解率为52.5%(21/40),确认缓解率为28.9%(11/38)。
核心结论
- IMA203在包括难治性黑色素瘤在内的多种实体瘤中显示出有前景的抗肿瘤活性。
研究设计与样本
- 首次人体、多中心、开放标签、3+3剂量递增/递减的1期试验,研究自体PRAME定向TCR T细胞疗法IMA203,用于HLA-A*02+的PRAME+复发和/或难治性实体瘤患者,包括黑色素瘤和肉瘤。
- 1a期剂量递增入组27例患者,1b期剂量扩展入组13例患者。
- 主要目标为评估安全性和耐受性并确定最大耐受剂量和/或扩展推荐剂量;次要目标包括评估IMA203 TCR工程化T细胞在外周血中的持久性、肿瘤缓解及缓解持续时间。
主要发现
- IMA203 T细胞安全,未达到最大耐受剂量。
- 41例接受治疗(即开始淋巴细胞清除)的患者中,严重细胞因子释放综合征发生率为4.9%(2/41),未发生严重神经毒性。
- 40例接受IMA203治疗的患者中,未确认或确认缓解的总体缓解率为52.5%(21/40),确认缓解率为28.9%(11/38),中位缓解持续时间为4.4个月(范围2.4-23.0,95%置信区间:2.6-未达到),涵盖多个适应症。
- 观察到IMA203 T细胞快速植入和长期持久性;IMA203 T细胞迁移至所有器官,较高剂量组患者中确认缓解更频繁。
- 外周未观察到T细胞耗竭;深度缓解在PRAME表达较高者中富集;T细胞浸润较高者无进展生存期更长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In contrast to chimeric antigen receptor T cells, T cell receptor (TCR)-engineered T cells can target intracellular tumor-associated antigens crucial for treating solid tumors. However, most trials published so far show limited clinical activity. Here we report interim data from a first-in-human, multicenter, open-label, 3 + 3 dose-escalation/de-escalation phase 1 trial studying IMA203, an autologous preferentially expressed antigen in melanoma (PRAME)-directed TCR T cell therapy in HLA-A*02+ patients with PRAME+ recurrent and/or refractory solid tumors, including melanoma and sarcoma. Primary objectives include the evaluation of safety and tolerability and the determination of the maximum tolerated dose (MTD) and/or recommended dose for extension. Secondary objectives include the evaluation of IMA203 TCR-engineered T cell persistence in peripheral blood, tumor response as well as duration of response. A total of 27 patients were enrolled in the phase 1a dose escalation and 13 patients in the phase 1b dose extension. IMA203 T cells were safe, and the MTD was not reached. Of the 41 patients receiving treatment (that is, who started lymphodepletion), severe cytokine release syndrome was observed in 4.9% (2/41), and severe neurotoxicity did not occur. In the 40 patients treated with IMA203, an overall response rate consisting of patients with unconfirmed or confirmed response (u/cORR) of 52.5% (21/40) and a cORR of 28.9% (11/38) was observed with a median duration of response of 4.4 months (range, 2.4-23.0, 95% confidence interval: 2.6-not reached) across multiple indications. Rapid T cell engraftment and long-term persistence of IMA203 T cells were observed. IMA203 T cells trafficked to all organs, and confirmed responses were more frequent in patients with higher dose. T cell exhaustion was not observed in the periphery; deep responses were enriched at higher PRAME expression; and higher T cell infiltration resulted in longer progression-free survival. Overall, IMA203 showed promising anti-tumor activity in multiple solid tumors, including refractory melanoma. ClinicalTrials.gov identifier: NCT03686124 .
引用
- Wermke M, Araujo DM, Chatterjee M, et al. Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial. Nat Med. 2025. PMID: 40205198. doi:10.1038/s41591-025-03650-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。